5. Conclusion

Molecular analysis of hematopoietic chimerism at a defined period after allo-HSCT represents a valuable non-specific marker of posttransplant course for all diagnoses. For some diagnoses this is the only available marker for monitoring. The aim of cell chimerism analysis is to provide a conclusive base for informed, clinical decision-making. The establishment of an adequate monitoring schedule, as well as the selection of appropriate markers and interpretation criteria, will improve the clinical value of this analysis. The use of sensitive methods, like RQ-PCR for the monitoring of cell chimerism, is important for the early detection of relapse and allows the early initiation of medical treatment.
